Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
IT0004147952
Wed, 01.12.2021
Newron Pharmaceuticals SpA
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy - Dec. 1, 2021 - Newron Pharmaceuticals S.p.A. ('Newron', SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Robert Leslie Holland has informed the Board [ … ]
Mon, 18.10.2021
Newron Pharmaceuticals SpA
Ad hoc announcement pursuant to Art. 53 SIX Listing Rules
Milan, Italy - October 18, 2021, 5:45 pm CEST - Newron Pharmaceuticals S.p.A. ('Newron') (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that it has received [ … ]
Thu, 16.09.2021
Newron Pharmaceuticals SpA
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, September 16, 2021, 07:00 am CEST - Newron Pharmaceuticals S.p.A. ('Newron') (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its operational highlights a [ … ]
Mon, 06.09.2021
Newron Pharmaceuticals SpA
Ad hoc announcement pursuant to Art. 53 SIX Listing Rules
Milan, Italy - September 6, 2021, 5.45 pm CEST - Newron Pharmaceutical S.p.A. ('Newron') (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that it has received [ … ]
Mon, 06.09.2021
Newron Pharmaceuticals SpA
Ad hoc announcement pursuant to Art. 53 SIX Listing Rules
Evenamide has the potential to be the first add-on therapy for patients with positive symptoms of schizophrenia
Four-week, double-blind, placebo-controlled study to evaluate safety and efficacy of therapeutic dose (30mg BID)
Minimum of 200 patients to be enrolled at study centers in Europe [ … ]
Thu, 20.05.2021
Newron Pharmaceuticals SpA
Milan, Italy - May 20, 2021 - Newron Pharmaceuticals S.p.A. ('Newron') (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that with reference to its media release of May 4, 2021, it received further Paragraph IV N [ … ]
Tue, 04.05.2021
Newron Pharmaceuticals SpA
Milan, Italy - May 4, 2021 - Newron Pharmaceuticals S.p.A. ('Newron') (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that it received a Paragraph IV Notice Letter regarding the submission by a generic manufact [ … ]
Tue, 13.04.2021
Newron Pharmaceuticals SpA
Milan, Italy - April 13, 2021 - Newron Pharmaceuticals S.p.A. ('Newron') (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announced that its shareholders approved the sole motion on the agenda of the AGM 2021 held today, being [ … ]
Thu, 01.04.2021
Newron Pharmaceuticals SpA
Primary objective of safety of evenamide met on all safety variables for study 010 in healthy volunteers and study 008 in patients with schizophrenia
Additional safety and efficacy study 008A in therapeutic dose (30 mg BID) to start in April 2021
Milan, Italy and Morristown, NJ, USA, April 1, 2021 - Newron Pharmaceuticals S.p.A. ('Newron') (SIX: [ … ]